BioArctic AB (OSTO:BIOA B) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BioArctic AB Debt-to-Asset?

BioArctic AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1.9 Mil. BioArctic AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr2.4 Mil. BioArctic AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr1,136.3 Mil. BioArctic AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

BioArctic AB Debt-to-Asset Historical Data

The historical data trend for BioArctic AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Debt-to-Asset Chart

BioArctic AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

BioArctic AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	-	-	-

Competitive Comparison of BioArctic AB's Debt-to-Asset

For the Biotechnology subindustry, BioArctic AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Debt-to-Asset falls into.

BioArctic AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioArctic AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.827	+	2.152)	/	1186.078
	=	0.00

BioArctic AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.939	+	2.381)	/	1136.334
	=	0.00

BioArctic AB (OSTO:BIOA B) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioArctic AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioArctic AB (OSTO:BIOA B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OSTO:BIOA B) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BRCTF:USA 0RV2:UK B9A:Germany

Address

Warfvinges vag 35, Stockholm, SWE, SE-112 51

Website

https://www.bioarctic.se

BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (OSTO:BIOA B) Headlines

No Headlines